Compare DUOT & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | KALA |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | 38 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.9M | 6.0M |
| IPO Year | N/A | 2017 |
| Metric | DUOT | KALA |
|---|---|---|
| Price | $9.08 | $0.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.75 | ★ $31.50 |
| AVG Volume (30 Days) | 214.3K | ★ 21.6M |
| Earning Date | 11-12-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,026,308.00 | N/A |
| Revenue This Year | $292.26 | N/A |
| Revenue Next Year | $43.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 159.00 | N/A |
| 52 Week Low | $3.84 | $0.55 |
| 52 Week High | $11.23 | $20.60 |
| Indicator | DUOT | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 35.48 |
| Support Level | $8.89 | $0.55 |
| Resistance Level | $10.67 | $0.86 |
| Average True Range (ATR) | 0.58 | 0.22 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 9.72 | 3.60 |
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.